Department of Chest Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey.
Tuberk Toraks. 2020 Sep;68(3):252-259. doi: 10.5578/tt.69934.
Chronic Obstructive Pulmonary Disease (COPD) exacerbations contribute to the overall severity in individual patients because they are associated with airway inflammation, pulmonary function loss, decreased quality of life and increased mortality. Although, identifying frequent exacerbator patients is important due to severe outcomes associated with frequent exacerbator phenotype in COPD patients there is no single biomarker which can differentiate this phenotype. Iron responding protein-2 (IRP2) is the protein product of IREB2 gene, which is a COPD susceptibility gene that regulates cellular iron homeostasis and has a key role in hypoxic conditions. Previous research indicates that IREB2 expression in lung tissue is associated with spirometric measurements and emphysema in COPD. In this study, our aim was to investigate whether serum IRP2 levels were associated with frequent exacerbator phenotype, to evaluate whether IRP2 levels in serum are associated with pulmonary functions and selected systemic inflammation biomarkers.
Designed as a single tertiary care center based, crosssectional study, included high risk (GOLD C, D) COPD patients who admitted to outpatient clinic consecutively between December 2015 and July 2016.
The study included 80 COPD patients. Serum IRP2 levels were negatively correlated with FEV1 ml (r= -0.25, p= 0.02) and body weight (r= -0.35, p= 0.002) but not with markers of systemic inflammation. COPD patients with at least one exacerbation history in the last year tended to have higher IRP2 levels than patients without any exacerbation [12.3 (IQR 25-75: 10.4- 17.1) vs 10.5 (IQR 25-75: 8.8-18.5), p= 0.06].
Serum IRP2 level is significantly correlated with FEV1 mL but not with FEV1 % predicted and cannot be used to differentiate frequent exacer bator patients. Although IREB2 gene expressions in lung tissue and bronchoalveolar lavage results have significant associations with emphysema and FEV1/FVC, FEV1 %predicted in COPD patients, our results suggests serum IRP2 level is not as promising.
慢性阻塞性肺疾病(COPD)加重会导致患者整体病情加重,因为它们与气道炎症、肺功能丧失、生活质量下降和死亡率增加有关。尽管由于 COPD 患者频繁加重表型与严重后果相关,因此识别频繁加重患者很重要,但目前还没有一种单一的生物标志物可以区分这种表型。铁反应蛋白-2(IRP2)是 IREB2 基因的蛋白产物,该基因是 COPD 的易感基因,调节细胞内铁稳态,在缺氧条件下发挥关键作用。先前的研究表明,肺组织中 IREB2 的表达与 COPD 患者的肺功能和肺气肿有关。在这项研究中,我们的目的是研究血清 IRP2 水平是否与频繁加重表型有关,评估血清 IRP2 水平是否与肺功能和选定的全身炎症生物标志物有关。
设计为一项基于单中心的横断面研究,纳入 2015 年 12 月至 2016 年 7 月连续入住门诊的高风险(GOLD C、D)COPD 患者。
该研究纳入了 80 例 COPD 患者。血清 IRP2 水平与 FEV1ml(r=-0.25,p=0.02)和体重(r=-0.35,p=0.002)呈负相关,但与全身炎症标志物无关。在过去一年中至少有一次加重史的 COPD 患者的 IRP2 水平高于无任何加重史的患者[12.3(IQR25-75:10.4-17.1)比 10.5(IQR25-75:8.8-18.5),p=0.06]。
血清 IRP2 水平与 FEV1ml 显著相关,但与 FEV1%pred 无关,不能用于区分频繁加重患者。尽管肺组织和支气管肺泡灌洗液中 IREB2 基因的表达与肺气肿和 COPD 患者的 FEV1/FVC、FEV1%pred 显著相关,但我们的结果表明,血清 IRP2 水平并不那么有前景。